The aim of this prospective study was to assess glomerular and tubular renal function before, and 1 and 2 years after hematological stem cell therapy (HSCT) in children and adolescents. 137 consecutive patients undergoing HSCT, for malignant diseases, were included in a prospective trial. Forty-four patients were followed for up to 1 year after HSCT and 36 for up to 2 years, without relapse. Ninety healthy school children were used as a control group. The following parameters were investigated: inulin clearance (GFR), urinary excretion of albumin, ␣ 1 -microglobulin (␣ 1 -MG), calcium, ␤-Nacetylglucosaminidase (␤-NAG) and Tamm-Horsfall protein (THP), tubular phosphate reabsorption (TP/Cl cr ) and percent reabsorption of amino acids (TAA). Significantly lower GFR was found 1 and 2 years after HSCT but within the normal range in the period before HSCT. There was no correlation between GFR within the first month after HSCT and long-term outcome of GFR. Tubular dysfunction was found in 14-45% of patients 1 and 2 years after HSCT depending on the parameter investigated. Pathological values 1 and 2 years after HSCT were found for ␣ 1 -MG excretion in 40% and 39%, respectively, for TP/Cl cr in 44% and 45%, for ␤-NAG in 26% and 19%. Median TP/Cl cr was significantly lower 2 years after HSCT than before. TAA was mildly impaired in 7/14 patients before, in 5/29 one and in 9/29 2 years after HSCT, but median TAA was within normal range at all times. The median excretion of albumin, THP and calcium was within the normal range at all investigations. No influence of ifosfamide pre-treatment on the severity of tubulopathy was found. The investigation of tubular renal function should be part of a long-term follow-up in children after HSCT. Bone Marrow Transplantation (2001) 27, 319-327.
Disturbances of renal function caused by chemotherapy or by supportive therapy in the treatment of malignancies are well-known and recognised. 1, 2 The pathogenesis of acute renal dysfunction is very often multifactorial and associated with the nephrotoxic potential of cytostatic agents (cisplatinum, ifosfamide), veno-occlusive disease, hepatorenal syndrome, sepsis and the corresponding antibiotic (aminogylcosides) and antifungal (amphotericin B) treatment. In patients treated with HSCT, acute renal dysfunction is a frequent complication 3, [4] [5] [6] [7] [8] [9] [10] and the effect of conditioning therapy for HSCT (high-dose chemotherapy and fractionated total body irradiation) on renal function in children has been published by our group earlier. 11 Chronic or long-term sequels of high-dose chemotherapy or HSCT have been less intensively investigated. [12] [13] [14] [15] [16] BMT-nephropathy (see Ref. 17 for review) has been found in up to 25% of transplanted adults and may progress to end-stage renal disease with a poor outcome in terms of survival on dialysis. Some renal injury syndromes are probably related to CyA, especially a hemolytic-uremic-like syndrome as firstly described by Shulman et al. 18 Radiation, cyclosporin A therapy, late effects of cytostatic treatment and graftversus-host disease are potential risk factors especially for renal tubular dysfunction and the development of ifosfamide-induced nephrotoxicity is well characterized. 19 It is also well-known that renal Fanconi syndrome may occur months or even years after the end of chemotherapy. 20 Nevertheless, no prospective trial has been published investigating frequency and pattern of tubulopathy in children undergoing HSCT.
The aim of this study was to assess glomerular and tubular renal function 1 and 2 years after successful HSCT in children in a prospective trial.
Patients and methods
Between 1992 and 1998, 137 patients suffering from malignant diseases were treated with a first bone marrow transplant or high-dose chemotherapy with autologous stem cell rescue in a single center. 128 patients were enrolled in a prospective trial to assess renal function before, during and after HSCT. Nine patients were not included because they did not give informed consent or were below the age of 2 years or because of likely loss to follow-up. Seventy children died within 365 days after HSCT, 12 suffered from relapse and two children were not available for follow-up. Forty-four relapse-free children were investigated 1 year after HSCT and 36 2 years after HSCT. For the analysis, patients were divided into two groups: group A, all patients with normal renal parameters prior to HSCT (n = 41); group B, unilaterally nephrectomized patients (n = 3). Because of the small number, group B will be shown only for description only and will not be used in any statistical evaluations. At the time of the investigation all children were well, in complete remission and without any acute illnesses.
Group A
One year after HSCT all were taking antibiotic prophylaxis (penicillin or cotrimoxazol), seven patients were receiving methotrexate, six CyA, one FK506, three prednisolone, four azathioprine, four 6-thioguanine and four 6-mercaptopurine. Only two patients were receiving phosphate and one calcium supplementation, respectively. Two years after HSCT all children were off CyA. Median age at HSCT was 13.6 (3.9-42) years. Ten patients were older than 16 years. Thirteen had acute lymphoblastic leukemia: six were transplanted in CR1, five in CR2, one in CR3 and one in incomplete remission. Nine had acute non-lymphoblastic leukemia: six in CR1, two in CR2 and one in first relapse. Four had chronic myeloid leukemia, four Hodgkin's lymphoma, two non-Hodgkin's lymphoma, two Ewing's sarcoma, two PNET, one rhabdomyosarcoma, one myelodysplastic syndrome, one osteosarcoma, one severe aplastic anemia and one neuroblastoma. Twenty-three patients underwent treatment before HSCT with protocols containing ifosfamide (median 10 g/m 2 IFO, range 2-86 g/m 2 , 2-10 g/m 2 n = 12, 20-24 g/m 2 n = 3, 30-48 g/m 2 n = 4, 54-86 g/m 2 n = 4), three patients had cisplatinum.
Twenty-one children received autologous and 20 allogeneical transplants (six matched unrelated donor, 10 matched related donor, three haploidentical related donor, one mismatched unrelated donor). Twenty-five patients were transplanted using bone marrow and 15 with stem cells, one patient received both on the same occasion. Distribution of kind of transplant in 33 relapse-free survivors 2 years after HSCT was similar compared to before HSCT (autologous n = 18, allogeneic n = 15, NS, -chi-square test). 
Group B

Conditioning regimens
The following conditioning regimens were used: Group A: combination containing cytostatic medications only, n = 27: (1) combination of busulfan (BU, 4 mg/kg for 4 days) and other cytostatics n = 18, (either cyclophosphamide, melphalan, etoposide, thiothepa or antithymocyte globulin); (2) others without fTBI, n = 9; (cyclophosphamide, etoposide, melphalan, carboplatin, AraC, carmustin). Values are median, 5th and 95th centile. Number of patients is given.
Group B: combinations containing fractionated total body irradiation (6 × 2 Gy) n = 14: (1) combination of fTBI and cytostatics (etoposide, melphalan), n = 8; (2) others with fTBI (cyclophosphamide, etoposide or ALG) n = 6.
Study design and laboratory investigations
Patients were investigated 20 days before, and 1 and 2 years after HSCT. A spot urine and a fasting blood sample were taken followed by inulin clearance. Urine samples for determination of ␣ 1 -MG, THP and albumin were frozen at −18°C until measurement. The following variables were investigated:
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Serum, urine:
The concentration of sodium and potassium was measured by ionsensitive electrodes. Calcium, phosphate, creatinine and urea were measured on a CX3/CX4 colorimetrically (Beckmann).
Statistics
All values are presented as median, minimum − maximum value. Statistical significance was judged by a P value of Ͻ0.05. Statistical procedures were performed using SPSS for Windows version 9.0 (SPSS Inc., Chicago, IL, USA). The statistical difference between values of two independent groups was done with the Mann-Whitney U-Wilcoxon rank sum W test. The Wilcoxon matched-pairs signed-ranks test was used to compare the results before and after HSCT. To compare three matched pair groups (before, 1 and 2 years after HSCT) the Friedman test was used. Correlation analysis to assess bivariate relationships was achieved by using the Spearman-Rho correlation test.
All investigations were made strictly in accordance with the guidelines of the local ethics committee.
Results
All children were free of urinary tract infection by dip stick testing at the time of investigation. Group A: median height standard deviation scores in children transplanted before the age of 12 years (n = 18) were +0.39 before, +0.16 1 year and −0.19 2 years after HSCT (P Ͻ 0.05, Friedman test). Seven patients (17%), all transplanted allogeneically and receiving CyA, suffered from acute renal insufficiency (doubling of serum creatinine) within 30 days after HSCT. Two of them had to be treated with renal replacement therapy because of multiorgan failure.
In Group B, one patient (No. 2) was transplanted with pre-existing renal Fanconi syndrome after 12 g/m 2 ifosfamide; tubulopathy persisted but is improving significantly.
Glomerular function
Glomerular filtration rate: Group A, GFR was significantly different before and 1 year after HSCT (130, 73-217 vs 123, 68-185 ml/min 1.73 m 2 , P Ͻ 0.05). It was within the normal range but significantly lower 2 years after HSCT compared to before (105, 81-177 ml/min 1.73 m 2 , P Ͻ 0.01). GFR was lower than 90 ml/min 1.73 m 2 in only one before, in two 1 year and in two patients 2 years after HSCT (Figure 1 ).
GFR after HSCT did not differ in seven patients who had acute renal failure within 30 days after HSCT compared to patients who did not double their serum creatinine: 109 ml/min 1.73 m no significant differences in GFR 2 years after HSCT with regard to the initial disease, type of conditioning regimen (containing fTBI or not) or kind of HSCT (data not shown).
We did not find significant differences in GFR regarding the presence of chronic GVHD at the time of investigation. Group B, GFR in patients 1, 2 and 3 was 117, 58 and 87 ml/min 1.73 m 2 before HSCT. One patient (No. 1) developed acute renal insufficiency and had to be treated with renal replacement therapy, patient 2 and 3 did not double their serum creatinine. GFRs 1 year after HSCT were 59, 54 and 127 ml/min 1.73 m 2 and 2 years after 83, 69 and 150 ml/min 1.73 m 2 (GFR was calculated by the Schwartz formula at 1 and 2 years after HSCT in patient 3 because he could not tolerate repeated inulin clearance).
Albumin excretion: Group A, median albumin excretion was found to be within the normal range and did not differ before, 1 and 2 years after HSCT: 1. Group B, ␣ 1 -MG-excretion was normal before HSCT before, 1 and 2 years after HSCT in patient 1 and 3; it was severely impaired on all investigations in patient 2 (43.5, 54.5, 10.9 mmol/l.). In this patient, improvement of ␣ 1 -MG-excretion correlated with improvement in TP/Cl cr and with albuminuria.
␤-NAG excretion:
Group A, urinary excretion of ␤-NAG was investigated in 31 patients. Median excretion and interquartile range are depicted in Figure 4 . It was significantly lower 1 year after HSCT compared to before and remained Bone Marrow Transplantation 
U/mmol creat (NS).
A highly significant correlation between ␤-NAG and ␣ 1 -MG excretion was found (Spearman coefficient 0.461, P Ͻ 0.001) using all measurements.
Group B, ␤-NAG was normal on all investigations in patient 1, and severely elevated on all measurements in patient 23 (4.31, 3.78, 1.86). It was not measured in patient 3.
Tamm-Horsfall protein excretion: median THP-excretion was within normal range and not significantly different before and after HSCT: 5.2, 0.8-15.2 vs 3.9, 1.5-11.9 vs 4.5, 1.2-9.2 mg/mmol creat. It was normal in the patients of group B on all measurements.
Calcium excretion: Group A, median calcium creatinine ratio on spot urine testing was within normal range (Ca/creat Ͻ0.7 mmol/mmol) and not significantly different before and after HSCT: 0.3, 0.02-2.7 mmol/mmol creat vs 0.21, 0.03-1.05 vs 0.22, 0.04-1.02 mmol/mmol creat. Eight patients had hypercalciuria before, 3/40 1 year after and 1/33 2 years after HSCT on the basis of spot urine testing (Ca/creat Ͼ0.7 mmol/mmol creat).
Group B, calcium/creatinine was normal in all patients on all investigations.
Reabsorption of amino acids:
Group A, reabsorption of amino acids was mildly impaired (reabsorption Ͻ2 s.d. of more than four amino acids) in 7/14 patients before, 5/29 1 year and in 9/29 2 years after HSCT. We did not find a correlation between reabsorption of amino acids and phosphate (Table 3a) . However, there was a significant correlation between frequency of impaired reabsorption of amino acids and ␣ 1 -MG (Table 3b ).
The median TAA 1 and 2 years after HSCT was within the normal range ( Figure 5 ). Two years after HSCT there was no significant difference in TAA of each amino acid between the group of patients with IFO pre-treatment and the group without treatment (data not shown).
Group B, TAA was severely impaired on all investigations in patient 2 (number of amino acids reabsorbed Ͻ2 s.d.: 9, 10, 4). TAA was normal 2 years after HSCT in patients 1 and 3.
Discussion
The aim of this study was to investigate frequency and pattern of renal tubulopathy 1 and 2 years following HSCT in children. Only children free of disease relapse were included in the analysis, resulting in a small group of patients treated in a single center. It is obvious that this kind of study is hampered by the non-homogeneous study group and the large number of independent influencing variables. The results presented here show important features concerning renal function during the course of highdose chemotherapy, obtained prospectively but they are not appropriate for defining an individual renal risk index for a given patient. Some studies have been published dealing with renal function after BMT, but for the first time we combined a prospective study design, the use of inulin clearance as measurement for GFR and investigation of a broad spectrum of tubular markers. Blood pressure, serum HCO 3 and response of urine osmolality to DDAVP were not tested within this study. The three unilaterally nephrectomized children were not included in the statistical analysis, but their individual courses are shown.
We found the median GFRs to be within the normal range in all investigations but it was significantly higher before HSCT compared to 1 and 2 years after. This indicates some degree of hyperfiltration prior to HSCT. Similar findings have been reported by Leblond et al, 15 who found significantly lower GFRs after HSCT compared to a group of adult patients before HSCT, in a non-prospective study. In contrast to our study, they found significantly lower GFRs in patients who received TBI. Lonnerholm et al 24 described normal GFR (Cr-EDTA clearance) 2 years after autologous HSCT in 15 children and found single fraction TBI to be a risk factor for deterioration. In contrast, Berg and Bolme 14 described decreased GFR (GFR estimation by the formula of Morris) before and at all yearly examinations after HSCT in children with ALL and AML. Kumar and co-workers 12 did not find significant long-term renal dysfunction in a retrospective study of 17 survivors who underwent BMT for acute lymphoblastic leukemia 2-10 years after transplantation, but they report hypertension, glucosuria and hematuria in two of them. Similar to our study, they found hyperfiltration in 10 patients, but the GFR was estimated by the Schwartz formula. Tubular parameters were not investigated in this study.
In our study, there was no correlation between GFR within the first month after HSCT and long-term outcome of GFR in long-term survivors. This is in contrast to the retrospective study from Kist et al 10 who found chronic renal insufficiency (GFR Ͻ85 ml/min 1.73 m 2 using Schwartz formula) in 25/90 children 1 year after BMT and a correlation of serum creatinine within 30 days after BMT, and renal insufficiency 1 year after BMT. The authors report acute renal insufficieny in 34% of patients compared to 17% in our study, and no patients who needed dialysis compared to two patients in our group A. Surprisingly, they found chronic renal failure in 28% of their children 1 year after BMT (7% in our group A). This result is difficult to interpret because no information about medication, especially CyA, on investigation 1 year after BMT was given by Kist et al. Van Why and co-workers 9 report renal insufficiency later than 60 days post BMT in 28% of 64 pediatric patients. In this investigation amphotericin B, CyA and TBI were found to be predictors for renal insufficiency. In accordance with our study and in contrast to Kist et al, renal insufficiency within 60 days after BMT was not predictive of late insufficiency in the study of van Why. The reason for the different conclusions about long-term prognosis of GFR may be attributed to the method used . As showed by Womer et al, 25 creatinine clearance is an unreliable measure of GFR in children but there are only a few reports using inulin-or Cr-EDTA clearance assessing GFR.
14,15,24,26 Reporting from our own experience, there is an extremely weak correlation between inulin clearance and GFR estimation from serum creatinine (Schwartz formula), especially in a group of patients with malignant disease. It is well-known that the Schwartz formula may overestimate GFR in patients with reduced muscle mass 27 and no methods estimating creatinine clearance from serum creatinine provide reliable methods for estimating GFR in pediatric patients about to undergo BMT. 28 Risk factors for deteriorating GFR seem to be single fraction TBI and BMT nephropathy as stated by Cohen et al in adults. 29, 30 BMT nephropathy particularly seems to bear a significant risk for progression into end-stage renal disease 31 and a poor survival on dialysis. We did not observe development of BMT nephropathy in our patient group. The reason for the low incidence remains unclear, the results of our study do not explain it. It may be possible that BMT nephropathy will develop later than 2 years after HSCT especially in a mainly pediatric population. We did not find any influence of chronic GVHD on GFR 1 and 2 years after HSCT and this is similar to the work of Leblond et al 15 who suggested that GVHD is not a major contributor to BMT nephropathy. However, in contrast, Miralbell et al 13 found a significant correlation between presence of GVHD and probability of renal dysfunction 18 months after BMT.
In the nephrectomized patients, the GFR was impaired before HSCT only in the patient with renal Fanconi syndrome, but it remained stable. One patient required dialysis because of extrarenal problems but kidney function showed marked recovery. Kapinga et al 32 report a retrospective analysis of 23 children treated with nephrectomy and highdose chemotherapy and abdominal radiotherapy. Ten patients developed impairment of creatinine clearance and five of seven survivors did not improve.
The bad prognosis of renal function in patients unilaterally nephrectomized for Wilms' tumour was also shown by Burk et al. 33 Thus, although reports from the literature show inconsistent findings, the prognosis of glomerular renal function seems to be good in long-term survivors of HSCT, independent of the initial disease, kind of HSCT and problems in the acute phase of HSCT. Our patients from group B show that unilateral nephrectomy and pre-existing renal Fanconi syndrome are not necessarily risk factors for developing chronic renal insufficiency after HSCT. It might be possible that some degree of hyperfiltration compensates for the reduction in nephrons for some years after HSCT. Because hyperfiltration by itself is clearly a risk factor for progression into renal failure, we advocate thorough follow-up of kidney function in these children for a long time.
In contrast to glomerular function, we were able to find tubular dysfunction in 14-45% of patients 1 and 2 years after HSCT depending on the parameter investigated. Although median ␣ 1 -MG excretion decreases over time after HSCT, 40% of patients regarded as healthy showed enhanced ␣ 1 -MG excretion 1 year after HSCT and 39% after 2 years, respectively. Pathological ␤-NAG excretion was found in 26% of patients 1 year and in 19% 2 years after HSCT. Median excretion of the brush border enzyme ␤-NAG was already normal 1 year after HSCT and only 5/26 patients showed significantly elevated ␤-NAG Bone Marrow Transplantation excretion 2 years after HSCT. Decreased phosphate reabsorption was found in 44% 1 year and in 45% 2 years after HSCT and median phosphate reabsorption worsened over time.
This indicates that the pattern of tubular damage changes over time. Early after HSCT, non-specific damage of proximal tubular cells is present as indicated by high excretion of the brush border enzyme ␤-NAG and by insufficiency of the different reabsorption systems (low molecular weight proteins, phosphate, amino acids). At a later stage, the signs of non-specific cell damage become less prominent but distinct damage, especially of phosphate reabsorption, persists. It is possible that the overall proximal cell injury caused by the conditioning therapy is being repaired within weeks or months after HSCT but only with defective healing of the phosphate transporter (most likely the sodium phosphate cotransporter type 2).
This hypothesis resembles the situation of impaired TP/Cl cr in patients with generalized tubulopathy after IFO published by Rossi et al. 20 Nonetheless, we did find higher cumulative probabilities for impaired phosphate reabsorption (44% vs 8% 1 year and 45% vs 14% 2 years after HSCT). Skinner and co-workers 19 report exactly the same incidence of pathological TP/Cl cr (44%) 1-47 (median 6) months after ifosfamide treatment in 103 children. In our study, not all patients with impaired TP/Cl cr 1 year after HSCT had impaired TP/Cl cr 2 years after HSCT. There was, however, a significant correlation between phosphate reabsorption 1 and 2 years after HSCT, indicating that impaired phosphate reabsorption 1 year after HSCT persists within the next year. We could not find any evidence that tubulopathy in our patient group was attributable to ifosfamide pre-treatment. There was no correlation between ifosfamide treatment and degree of tubulopathy 1 or 2 years after HSCT. The reason could be the relatively low dose of ifosfamide in our group of patients who predominantly had leukemia, as compared to patients receiving high-dose ifosfamide therapy for osteosarcoma or rhabdomyosarcoma. Rossi et al 34 also failed to show a linear correlation between cumulative IFO dose and phosphate reabsorption. Low TP/Cl cr values were found in this study only with IFO doses above 24 g/m 2 , but in a number of patients it was present even after high IFO doses. We also found impaired TP/Cl cr in children who had never had IFO or cisplatinum.
We did not investigate the sequelae of phosphate loss on growth and bone metabolism in this study. However, disturbances in bone turnover in children after completion of chemotherapy and impaired final height after HSCT in childhood are reported [35] [36] [37] and it is possible that renal phosphate loss may contribute to disturbed bone metabolism and to the well-documented growth impairment after HSCT.
Amino acid reabsorption was impaired in 17% and in 31% patients 1 and 2 years after HSCT, respectively. In contrast to Rossi et al 20 and Caron et al 38 we were not able to prove that early impaired amino acid reabsorption progresses to generalized tubulopathy or renal Fanconi syndrome. We did not observe the development of complete Fanconi syndrome within 2 years after HSCT in a patient who had not received IFO.
From the normal excretion of THP, it seems that the dis-tal tubule and thick ascending loop of Henlé are not affected at all after HSCT. Our investigations of tubular function indicate significant residual tubulopathy 1 and 2 years after HSCT. Reasons for this tubulopathy are probably multifactorial. Because of the small number of patients and the heterogeneity of the group with regard to diagnosis, pre-treatment, conditioning regimens, type of HSCT, etc, it was not possible to define independent causes for tubulopathy. Cumulative nephrotoxicity during conventional chemotherapy (ifosfamide, cisplatinum), conditioning regimen prior to HSCT, septicemia and its supportive therapy, GVHD and medication at the time of our investigation (CyA, cotrimoxazol) may all have contributed to the impairment of renal proximal tubular function. It is possible, that the different nephrotoxic events are cumulative, but by the methods used it is not possible to distinguish between tubulopathy caused by nephrotoxic drugs from tubulopathy caused by GVHD.
Our three unilaterally nephrectomized children indicate that neither nephrectomy nor pre-existing renal Fanconi syndrome by itself are risk factors for HSCT.
Conclusion
The prognosis of glomerular renal function in healthy longterm survivors of HSCT is good. In contrast, about 40% of patients including those without prior exposure to IFO show significant signs of tubulopathy, especially phosphate loss. Whereas phosphate and bicarbonate loss are likely to result in clinically relevant problems, pathological excretion of ␤-NAG, ␣ 1 -MG and amino acids will not cause problems per se. Nevertheless, they are important indicators of the integrity and function of the proximal tubular cells. It is possible that glucosuria, hypercalciuria, enzymuria or microproteinuria are the first signs of progressive renal damage as known from distinct renal diseases (Fanconi syndrome in cystinosis, Dent's disease, tyrosinemia). Unfortunately, no predictors have been found to differentiate children with ongoing renal damage who need follow-up from patients with harmless pathological values.
The significance of isolated renal phosphate loss on growth and bone metabolism needs to be determined by further prospective, multicenter studies. Based on our investigations and reports from the literature, investigation of tubular renal function -especially phosphate reabsorption -should be part of the long-term follow-up in children after HSCT especially in those with pre-existing renal problems, such as unilateral nephrectomy or renal Fanconi syndrome.
